Abstract
Seventeen children with recurrent medulloblastoma and ependymoma received PCNU (100 mg/m2) in a Phase II trial. Response was evaluated by CAT scan. There were no responses. Administration of PCNU was associated with significant thrombocytopenia.
MeSH terms
-
Adolescent
-
Brain Neoplasms / drug therapy*
-
Child
-
Child, Preschool
-
Drug Evaluation
-
Ependymoma / drug therapy*
-
Humans
-
Medulloblastoma / drug therapy*
-
Neoplasm Recurrence, Local / drug therapy
-
Nitrosourea Compounds / adverse effects
-
Nitrosourea Compounds / therapeutic use*
-
Thrombocytopenia / chemically induced
-
Tomography, X-Ray Computed
Substances
-
Nitrosourea Compounds
-
1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea